Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Paroxysmal nocturnal hemoglobinuria

Known as: Hemoglobinuria, Paroxysmal Nocturnal, Nocturnal Paroxysmal Hemoglobinuria, PNH 
A rare disorder in which red blood cells are easily destroyed by certain immune system proteins. Symptoms include blood clots, and red or brownish… 
National Institutes of Health

Related topics

Related topics

8 relations
Cold paroxysmal hemoglobinuriaHematopoietic and Lymphoid CellHematopoietic and Lymphoid TissuePAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1
Expand

Broader (2)

HemoglobinuriaHemoglobinuria, Paroxysmal

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal… 
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2007
Highly Cited
2007
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders. In paroxysmal nocturnal… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 5
Highly Cited
2006
Highly Cited
2006
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
BACKGROUND We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein… 
Review
2005
Review
2005
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
The primary clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH) are hemolytic anemia, marrow failure, and… 
  • table 3
  • table 4
  • table 2
  • figure 1
  • table 6
Review
2005
Review
2005
Practice parameters for the indications for polysomnography and related procedures: an update for 2005.
These practice parameters are an update of the previously-published recommendations regarding the indications for polysomnography… 
  • table 1
  • table 3
  • table 4
  • table 5
Highly Cited
2004
Highly Cited
2004
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
1999
Highly Cited
1999
Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.
In paroxysmal nocturnal hemoglobinuria (PNH), acquired somatic mutations in the PIG-A gene give rise to clonal populations of red… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
1995
Highly Cited
1995
Natural history of paroxysmal nocturnal hemoglobinuria.
BACKGROUND Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is… 
Highly Cited
1993
Highly Cited
1993
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE